Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Public ClinicalTrials.gov record NCT05317416. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years
Study identification
- NCT ID
- NCT05317416
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 854 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 2022 (Actual)
- Primary completion
- Aug 4, 2027 (Estimated)
- Completion
- Oct 31, 2029 (Estimated)
- Last update posted
- Apr 16, 2026
2022 – 2029
United States locations
- U.S. sites
- 24
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner Gateway Medical Center | Gilbert | Arizona | 85234 | — |
| Banner Gateway Medical Pavilion | Gilbert | Arizona | 85234 | — |
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Ronald Reagan UCLA Medical Center | Los Angeles | California | 90095 | — |
| UCLA Department of Medicine - Hematology/Oncology | Los Angeles | California | 90095 | — |
| UCLA Hematology/Oncology | Los Angeles | California | 90095 | — |
| Santa Monica UCLA Medical Center & Orthopaedic Hospital | Santa Monica | California | 90404 | — |
| UCLA Hematology/Oncology - Santa Monica | Santa Monica | California | 90404 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Miami Cancer Institute at Baptist Health, Inc. | Miami | Florida | 33176 | — |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322 | — |
| Loyola University Chicago | Maywood | Illinois | 60153 | — |
| Ascentist Doctor Hospital | Leawood | Kansas | 66211 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| American Oncology Partners, P.A. Dba MidAmerica Cancer Care | Kansas City | Missouri | 64132 | — |
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| WMCHealth Advanced Physician Services | Hawthorne | New York | 10532 | — |
| Westchester Medical Center | Valhalla | New York | 10595 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| OhioHealth Arthur G.H. Bing, MD, Cancer Center | Columbus | Ohio | 43214 | — |
| OhioHealth Research Institute | Columbus | Ohio | 43214 | — |
| OhioHealth Riverside Methodist Hospital | Columbus | Ohio | 43214 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| Baylor Scott & White Medical Center - Temple | Temple | Texas | 76508 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 185 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05317416, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05317416 live on ClinicalTrials.gov.